A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer Academic Article uri icon

Overview

MeSH Major

  • Aminoquinolines
  • Aniline Compounds
  • Deoxycytidine
  • Fluorouracil

abstract

  • In advanced colorectal cancer, 50 mg EKB-569 daily can be safely combined with 1,000 mg/m(2) capecitabine twice a day. A statistically significant increase in plasma levels of 5-fluorouracil for the combination of EKB-569 and capecitabine may be due to the single-dose versus multiple-dose exposure difference, variability in exposure or a potential drug interaction.

publication date

  • September 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3086427

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-08-0433

PubMed ID

  • 18765554

Additional Document Info

start page

  • 5602

end page

  • 9

volume

  • 14

number

  • 17